| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 27 August 2026 - 15:00

Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 27 August 2026 - 14:54

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 21, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Hemgenix, etranacogene dezaparvovec, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 27 August 2026 - 14:44

Human medicines European public assessment report (EPAR): Hemgenix, etranacogene dezaparvovec, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Hemgenix, etranacogene dezaparvovec, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 27 August 2026 - 14:06

Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Voranigo, vorasidenib, Date of authorisation: 17/09/2025, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 27 August 2026 - 14:00

Human medicines European public assessment report (EPAR): Voranigo, vorasidenib, Date of authorisation: 17/09/2025, Revision: 3, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Voranigo, vorasidenib, Date of authorisation: 17/09/2025, Revision: 3, Status: Authorised

Paliperidone palmitate

Submitted by Anonymous (not verified) on 27 August 2026 - 13:00

Paliperidone palmitate

Read more about Paliperidone palmitate

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation: 23/08/2022, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 27 August 2026 - 10:50

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation: 23/08/2022, Revision: 10, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation: 23/08/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 27 August 2026 - 9:16

Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 10, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Kauliv, teriparatide, Date of authorisation: 12/01/2023, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 27 August 2026 - 9:07

Human medicines European public assessment report (EPAR): Kauliv, teriparatide, Date of authorisation: 12/01/2023, Revision: 4, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Kauliv, teriparatide, Date of authorisation: 12/01/2023, Revision: 4, Status: Authorised

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Hemgenix, etranacogene dezaparvovec, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Voranigo, vorasidenib, Date of authorisation: 17/09/2025, Revision: 3, Status: Authorised

Paliperidone palmitate

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation: 23/08/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Kauliv, teriparatide, Date of authorisation: 12/01/2023, Revision: 4, Status: Authorised

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters